RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 3 TRIAL OF TRIUMEQ IN AMYOTROPHIC LATERAL SCLEROSIS - LIGHTHOUSE II

This study, named LIGHTHOUSE II, is a research project designed to explore a new potential treatment for Amyotrophic Lateral Sclerosis (ALS), which is also known as Motor Neuron Disease. ALS is a condition that affects nerve cells in the brain and spinal cord, leading to muscle weakness and problems with movement. The medicine being tested is called Triumeq. Researchers want to understand if Triumeq can help people with ALS live longer and maintain their daily abilities.

To make sure the study gives reliable results, it's set up in a particular way. Some participants will receive the active medicine, Triumeq, while others will receive a 'dummy pill', called a placebo. This placebo looks exactly like the Triumeq tablets and tastes the same. This method is used because people's expectations can sometimes influence how they feel, and comparing to a placebo helps us truly see if the medicine is having a real effect. Neither you nor your doctor will know whether you are receiving Triumeq or the placebo until the study is over. This is called a "double-blind" study.

The main thing the researchers will be looking at is how long people live in the study. They will also be closely watching many other aspects of health, such as daily functioning (like your ability to do everyday tasks), your breathing, your overall quality of life, and any changes in your thinking. They will also carefully check for any side effects from the treatment to ensure it is safe and well-tolerated.